[{"data":1,"prerenderedAt":356},["ShallowReactive",2],{"content-route-/en/symptoms-conditions/sifo":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":19,"projection":157,"alternates":347},"target","/en/symptoms-conditions/sifo","en-US",{"kind":8,"family":9,"sectionKeys":10},"condition","guidance",[11,12,13,14,15,16,17,18],"definition","stages","diagnosis-states","differentials","options","expected-course","recurrence","evidence",{"kind":8,"title":20,"description":21,"firstPublished":22,"evidenceAsOf":22,"lastUpdated":22,"changeNote":23,"firstLayer":24,"stageRoutes":54,"differentials":56,"relations":71,"body":100},"SIFO: what small intestinal fungal overgrowth is and is not","Understand what SIFO (small intestinal fungal overgrowth) actually means, how limited its evidence base is, who it applies to, and how it differs from a broad self-diagnosed \"candida overgrowth.\"","2026-07-15","Complete initial draft based on the Pathway B terminology and US authority packs.",{"question":25,"answer":26,"keyPoints":27,"confidence":31,"applicability":34,"nextSteps":41},"What is SIFO, and does it mean I have \"candida overgrowth\"?","SIFO (small intestinal fungal overgrowth) is a narrow clinical-research term for excessive fungal growth found on culture of small-intestinal aspirate in people with unexplained gastrointestinal symptoms. It is a real but limited research finding from specialist evaluation, not a confirmed everyday diagnosis, and it does not validate a broad, self-diagnosed \"candida overgrowth\" syndrome.",[28,29,30],"The evidence behind SIFO is small, comes largely from one research group, and has no standardized diagnostic protocol; it is defined by aspirate culture, not by symptoms alone.","Bloating, belching, indigestion, nausea, gas, diarrhea, and abdominal discomfort are common to SIFO and to people without cultured overgrowth, so symptoms alone cannot identify it.","Whether antifungal treatment durably improves symptoms or eradicates the overgrowth remains unresolved; no adequate controlled treatment evidence has been identified.",{"summary":32,"rationale":33},"Strong confidence that SIFO is a narrow, aspirate-defined research entity with an early and limited evidence base; not enough evidence to state that treatment produces durable benefit or eradication.","A single-center observational study and a subsequent clinical review consistently define SIFO by small-intestinal aspirate culture in selected symptomatic patients and describe symptoms as nonspecific; no identified guideline or controlled trial resolves treatment benefit, duration, or relapse.",{"appliesTo":35,"excludes":38},[36,37],"Adults with persistent, otherwise-unexplained gastrointestinal symptoms after unrevealing routine evaluation who are considering, or have been offered, specialist small-intestinal testing.","People who have read or heard the term SIFO and want to know what it does and does not establish before applying it to their own symptoms.",[39,40],"People with an immediate medical emergency or acute emotional crisis, who should use the urgent-help route now.","People seeking confirmation of a broad, whole-body \"candida overgrowth\" self-diagnosis; SIFO is a narrower, site-specific research finding and does not support that broader claim.",[42,46,50],{"label":43,"action":44,"route":45},"Check the terms in play","See how SIFO, candidiasis, invasive candidiasis, and \"candida overgrowth\" differ before applying any of them to your symptoms.","/en/symptoms-conditions/candida-terms",{"label":47,"action":48,"route":49},"Prepare questions for a clinician","Use a structured worksheet to bring your exact symptoms and any candida-related claim to a clinician for evaluation.","/en/tools/candida-claim-clinician-questions",{"label":51,"action":52,"route":53},"Review urgent routes","Confirm whether any symptom needs urgent rather than routine care.","/en/urgent-help",{"firstTime":55,"recurring":55,"treatmentFailed":55},"/en/start-here/check-a-candida-claim",[57,61,64,67],{"label":58,"discriminator":59,"route":60},"Functional gastrointestinal disorders, including irritable bowel syndrome","Bloating, gas, and abdominal discomfort overlap closely with SIFO's reported symptoms and are far more common, so functional disorders should be considered alongside or instead of fungal overgrowth.","/en/treatments-evidence/candida-tests",{"label":62,"discriminator":63,"route":60},"Small intestinal bacterial overgrowth","The same study population that yields fungal overgrowth findings also yields bacterial overgrowth, sometimes together; symptoms alone do not distinguish bacterial from fungal overgrowth or from no overgrowth.",{"label":65,"discriminator":66,"route":60},"Motility disorders","Proton pump inhibitor use and dysmotility are described as independent risk factors for cultured small-intestinal overgrowth, so an underlying motility problem can produce or contribute to the same symptom pattern.",{"label":68,"discriminator":69,"route":70},"Medication effects or dietary intolerance","Medicines that alter gut acidity or motility, and food intolerances, can produce bloating, gas, and abdominal discomfort that resemble reported SIFO symptoms without any cultured overgrowth.","/en/treatments-evidence/candida-diet",[72,76,79,82,84,87,90,93,97],{"group":73,"route":74,"label":75},"parent","/en/symptoms-conditions","Symptoms & conditions",{"group":77,"route":45,"label":78},"differential","Candida and \"candida overgrowth\" terms",{"group":80,"route":60,"label":81},"treatment","Candida tests",{"group":80,"route":70,"label":83},"Candida diet",{"group":80,"route":85,"label":86},"/en/treatments-evidence/candida-overgrowth-claim","The \"candida overgrowth\" claim",{"group":18,"route":88,"label":89},"/en/research/evidence/broad-candida-claims","Broad candida claims: evidence map",{"group":91,"route":49,"label":92},"tool","Candida claim clinician questions",{"group":94,"route":95,"label":96},"research","/en/research/sifo-aspirate-symptoms-2013","SIFO aspirate and symptoms (2013)",{"group":98,"route":53,"label":99},"safety","Urgent help",{"type":101,"value":102,"toc":153},"minimark",[103,111,117,123,129,135,141,147],[104,105,107],"content-section",{"section-key":11,"title":106},"What SIFO is—and is not",[108,109,110],"p",{},"SIFO (small intestinal fungal overgrowth) is a narrow clinical-research label for excessive fungal growth detected in small-intestinal aspirate in a person with gastrointestinal symptoms. It is not interchangeable with normal gut Candida carriage, invasive candidiasis, or a broad multisystem \"candida overgrowth\" syndrome. The evidence base is small, largely from one research group, and there is no standardized diagnostic protocol.",[104,112,114],{"section-key":12,"title":113},"Symptoms alone do not identify SIFO",[108,115,116],{},"Bloating, belching, indigestion, nausea, gas, diarrhea, and abdominal discomfort are the symptoms most often linked to SIFO, but the same symptom profile occurs in people without cultured bacterial or fungal overgrowth. Symptoms can orient further evaluation, but they cannot establish SIFO on their own; only aspirate culture from specialist evaluation does that.",[104,118,120],{"section-key":13,"title":119},"Confirmed SIFO, unexplained symptoms, or self-attributed candida overgrowth",[108,121,122],{},"Aspirate-confirmed SIFO, unexplained gastrointestinal symptoms without that confirmation, and symptoms self-attributed to a broad \"candida overgrowth\" are three different situations. Only the first has direct research support for the SIFO label itself, and even then the research population is small and selected. The second calls for further evaluation. The third extends the term beyond what the evidence supports and is addressed separately on the \"candida overgrowth\" claim page.",[104,124,126],{"section-key":14,"title":125},"What else can look like SIFO",[108,127,128],{},"Functional gastrointestinal disorders such as irritable bowel syndrome, small intestinal bacterial overgrowth, motility disorders (including effects linked to proton pump inhibitor use), and medication or dietary effects can all produce a similar symptom pattern. Because symptoms overlap so closely, reassessment and appropriate testing matter more than assuming fungal overgrowth is the cause.",[104,130,132],{"section-key":15,"title":131},"What testing and care look like",[108,133,134],{},"Specialist evaluation, including small-intestinal aspirate culture, is what distinguishes SIFO from these other causes; no home test or symptom checklist substitutes for it. Diet claims and supplement products marketed for \"candida overgrowth\" do not have established evidence for treating SIFO. Anyone starting a supplement for a candida-related purpose while pregnant, breastfeeding, a child, on other medicines or supplements, or with a planned surgery or recent health change should have the exact product reviewed by a physician, pharmacist, or dietitian first; a serious reaction to such a supplement needs immediate medical care.",[104,136,138],{"section-key":16,"title":137},"Expected course and unresolved treatment benefit",[108,139,140],{},"No adequate controlled evidence shows that antifungal treatment durably improves symptoms or eradicates the overgrowth on repeat culture. Persistent or unresponsive symptoms are a reason to return for reassessment rather than a sign that a fungal cause has been proven or that repeated antifungal use is warranted.",[104,142,144],{"section-key":17,"title":143},"Safety and urgent routes",[108,145,146],{},"SIFO and its differentials are not urgent conditions by themselves. If someone describes worsening or \"die-off\" during a candida-labeled diet, supplement, probiotic, or antifungal and says they are thinking about suicide, cannot stay safe, or are in acute emotional crisis, call or text 988 or use 988 Lifeline chat now. Anyone with a serious reaction to a supplement, such as throat, lip, or tongue swelling, wheezing, fainting, chest pain, or severe persistent vomiting, diarrhea, or abdominal pain, should stop the supplement and seek immediate medical care.",[104,148,150],{"section-key":18,"title":149},"Evidence and sources",[108,151,152],{},"The linked evidence map traces the SIFO, symptom-discrimination, treatment-benefit, and broad \"candida overgrowth\" claims to their populations, limits, original sources, and research summaries. This page remains a draft until its planned pathway relations are available for publication.",{"title":154,"searchDepth":155,"depth":155,"links":156},"",2,[],{"sources":158,"claims":203,"safety":290},[159,167,175,183,187,195],{"sourceId":160,"title":161,"canonicalId":162,"canonicalUrl":163,"publisher":164,"sourceType":165,"publicationDate":166,"lastChecked":22},"jacobs-small-intestinal-overgrowth-2013","Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth","PMID:23574267; DOI:10.1111/apt.12304","https://pubmed.ncbi.nlm.nih.gov/23574267/","Alimentary Pharmacology & Therapeutics","observational-study","2013-06-01",{"sourceId":168,"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},"erdogan-sifo-review-2015","Small intestinal fungal overgrowth","PMID:25786900; DOI:10.1007/s11894-015-0436-2","https://pubmed.ncbi.nlm.nih.gov/25786900/","Current Gastroenterology Reports","other","2015-04-01",{"sourceId":176,"title":177,"canonicalId":178,"canonicalUrl":179,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},"cdc-invasive-candidiasis-overview-2024","Clinical Overview of Invasive Candidiasis",null,"https://www.cdc.gov/candidiasis/hcp/clinical-overview/","US Centers for Disease Control and Prevention","regulator","2024-04-24",{"sourceId":184,"title":185,"canonicalId":178,"canonicalUrl":186,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},"cdc-candidiasis-basics-2024","Candidiasis Basics","https://www.cdc.gov/candidiasis/about/index.html",{"sourceId":188,"title":189,"canonicalId":190,"canonicalUrl":191,"publisher":192,"sourceType":193,"publicationDate":194,"lastChecked":22},"idsa-candidiasis-guideline-2016","Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","guideline","2016-02-15",{"sourceId":196,"title":197,"canonicalId":198,"canonicalUrl":199,"publisher":200,"sourceType":201,"publicationDate":202,"lastChecked":22},"lacour-intestinal-candida-systematic-review-2002","The pathogenetic significance of intestinal Candida colonization: a systematic review from an interdisciplinary and environmental medical point of view","PMID:12068745; DOI:10.1078/1438-4639-00159","https://pubmed.ncbi.nlm.nih.gov/12068745/","International Journal of Hygiene and Environmental Health","systematic-review","2002-05-01",[204,219,230,245,257,279],{"claimId":205,"exactClaim":206,"outcome":207,"population":208,"verdict":209,"evidenceLevel":210,"rationale":211,"safetyStatus":212,"evidenceAsOf":22,"lastUpdated":22,"status":213,"changeHistory":214,"sources":215},"sifo-is-narrow-clinical-research-entity","Small intestinal fungal overgrowth (SIFO) is a narrow clinical-research label for excessive fungal growth detected in small-intestinal aspirate in a person with gastrointestinal symptoms; it is not interchangeable with normal gut Candida carriage, invasive candidiasis, or a broad multisystem 'Candida overgrowth' syndrome.","correct identification of the population, sampling site, and disease boundaries represented by the term SIFO","adults with persistent otherwise-unexplained gastrointestinal symptoms considered for specialist small-intestinal evaluation","supported","early","The 2013 single-center study and 2015 clinical review consistently use SIFO for fungal growth from duodenal or small-intestinal aspirate in selected symptomatic patients. The literature is small, largely from one investigator group, and lacks a standardized diagnostic protocol, so this supports a terminology boundary rather than a mature broadly applicable diagnosis.","usual-cautions","active",[],[216,217,218],{"title":161,"canonicalId":162,"canonicalUrl":163,"publisher":164,"sourceType":165,"publicationDate":166,"lastChecked":22},{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":177,"canonicalId":178,"canonicalUrl":179,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"claimId":220,"exactClaim":221,"outcome":222,"population":223,"verdict":224,"evidenceLevel":210,"rationale":225,"safetyStatus":212,"evidenceAsOf":22,"lastUpdated":22,"status":213,"changeHistory":226,"sources":227},"sifo-symptoms-alone-identify-overgrowth","Bloating, belching, indigestion, nausea, gas, diarrhea, or abdominal discomfort alone can identify which adults with unexplained gastrointestinal symptoms have SIFO.","diagnostic discrimination between SIFO, mixed bacterial/fungal overgrowth, and no cultured small-intestinal overgrowth based on symptoms alone","adults with persistent gastrointestinal complaints after unrevealing routine endoscopic or radiologic evaluation","not-supported","In the 150-person single-center observational study, symptom profiles were similar with and without cultured bacterial or fungal overgrowth. The 2015 review likewise describes common symptoms as nonspecific. Symptoms therefore orient further evaluation but do not establish SIFO; alternatives include functional gastrointestinal disorders, bacterial overgrowth, motility disorders, medication effects, dietary intolerance, and other gastrointestinal disease.",[],[228,229],{"title":161,"canonicalId":162,"canonicalUrl":163,"publisher":164,"sourceType":165,"publicationDate":166,"lastChecked":22},{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"claimId":231,"exactClaim":232,"outcome":233,"population":234,"verdict":235,"evidenceLevel":236,"rationale":237,"safetyStatus":238,"evidenceAsOf":22,"lastUpdated":22,"status":239,"changeHistory":240,"sources":241},"sifo-antifungal-symptom-benefit","Antifungal treatment produces durable symptom improvement and eradicates excessive small-intestinal fungal growth in immunocompetent adults with aspirate-defined SIFO.","durable improvement in gastrointestinal symptoms and confirmed eradication on repeat small-intestinal aspirate culture","immunocompetent adults with persistent gastrointestinal symptoms and SIFO defined by fungal growth from a small-intestinal aspirate","not-enough-evidence","unclear","The available clinical review states that whether eradication or treatment resolves symptoms remains unclear and that evidence for eradication is lacking. The key observational study evaluated association and diagnostic discrimination rather than comparative treatment effectiveness. No current guideline or controlled treatment synthesis identified in the final search resolves benefit, duration, relapse, or patient selection.","elevated-risk","blocked",[],[242,243,244],{"title":161,"canonicalId":162,"canonicalUrl":163,"publisher":164,"sourceType":165,"publicationDate":166,"lastChecked":22},{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"title":189,"canonicalId":190,"canonicalUrl":191,"publisher":192,"sourceType":193,"publicationDate":194,"lastChecked":22},{"claimId":246,"exactClaim":247,"outcome":248,"population":249,"verdict":209,"evidenceLevel":250,"rationale":251,"safetyStatus":212,"evidenceAsOf":22,"lastUpdated":22,"status":213,"changeHistory":252,"sources":253},"candidiasis-is-site-specific-disease-not-candida-presence","Candidiasis names disease caused by Candida at a defined body site; the presence of Candida on skin or in the mouth, gastrointestinal tract, or vagina without compatible disease does not itself establish candidiasis.","correct distinction between recognized site-specific candidiasis and asymptomatic Candida carriage or colonization","adolescents and adults encountering Candida terminology or a Candida finding from a nonsterile body site","strong","CDC describes Candida as normally present at several body sites and candidiasis as infection when it causes site-dependent disease. CDC and IDSA separately describe gastrointestinal, skin, and respiratory colonization and do not equate a nonsterile-site finding with invasive or mucosal disease.",[],[254,255,256],{"title":185,"canonicalId":178,"canonicalUrl":186,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":177,"canonicalId":178,"canonicalUrl":179,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":189,"canonicalId":190,"canonicalUrl":191,"publisher":192,"sourceType":193,"publicationDate":194,"lastChecked":22},{"claimId":258,"exactClaim":259,"outcome":260,"population":261,"verdict":224,"evidenceLevel":262,"rationale":263,"safetyStatus":212,"evidenceAsOf":22,"lastUpdated":22,"status":213,"changeHistory":264,"sources":265},"broad-candida-symptom-cluster-establishes-cause","A broad cluster of nonspecific symptoms such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints establishes intestinal Candida overgrowth as their shared cause.","valid causal attribution of a nonspecific multisystem symptom cluster to intestinal Candida overgrowth","immunocompetent adolescents and adults with chronic gastrointestinal and/or extraintestinal symptoms but without established site-specific or invasive candidiasis","moderate","A systematic review of 96 eligible citations found intestinal Candida colonization common in healthy immunocompetent adults and found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome. Current CDC and IDSA disease definitions do not recognize a symptom-list diagnosis of systemic or intestinal candidiasis. The controlled nystatin trial in women meeting proposed candidiasis-hypersensitivity criteria found no meaningful advantage over placebo for systemic or psychological symptoms. Early SIFO studies concern a narrower, selected gastrointestinal population assessed by small-bowel aspirate and cannot validate a broad multisystem syndrome. Plausible alternatives depend on the symptom pattern and include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections; the attribution should stop and pivot to evaluation of the actual symptoms when a recognized Candida condition has not been established.",[],[266,267,268,269,270,277,278],{"title":197,"canonicalId":198,"canonicalUrl":199,"publisher":200,"sourceType":201,"publicationDate":202,"lastChecked":22},{"title":185,"canonicalId":178,"canonicalUrl":186,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":177,"canonicalId":178,"canonicalUrl":179,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":189,"canonicalId":190,"canonicalUrl":191,"publisher":192,"sourceType":193,"publicationDate":194,"lastChecked":22},{"title":271,"canonicalId":272,"canonicalUrl":273,"publisher":274,"sourceType":275,"publicationDate":276,"lastChecked":22},"A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome","PMID:2247104; DOI:10.1056/NEJM199012203232501","https://pubmed.ncbi.nlm.nih.gov/2247104/","New England Journal of Medicine","randomized-trial","1990-12-20",{"title":161,"canonicalId":162,"canonicalUrl":163,"publisher":164,"sourceType":165,"publicationDate":166,"lastChecked":22},{"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":172,"sourceType":173,"publicationDate":174,"lastChecked":22},{"claimId":280,"exactClaim":281,"outcome":282,"population":283,"verdict":209,"evidenceLevel":250,"rationale":284,"safetyStatus":212,"evidenceAsOf":22,"lastUpdated":22,"status":213,"changeHistory":285,"sources":286},"invasive-candidiasis-is-not-vernacular-systemic-candida","Recognized invasive candidiasis is infection of the bloodstream or normally sterile internal sites in high-risk clinical populations; it is not a synonym for a self-attributed chronic multisystem symptom pattern called 'systemic Candida' or 'whole-body Candida overgrowth.'","accurate separation of invasive candidiasis from vernacular broad-overgrowth labels","adolescents and adults using broad Candida terminology for chronic gastrointestinal, fatigue, cognitive, mood, skin, or other nonspecific symptoms","CDC and IDSA define invasive candidiasis by invasive disease entities, risk context, cultures, and affected sterile sites. Their definitions do not map nonspecific chronic symptom lists in otherwise stable community populations to invasive candidiasis. This terminology boundary does not rule out a person's symptoms; it stops the invasive-disease label from being inferred from them.",[],[287,288,289],{"title":185,"canonicalId":178,"canonicalUrl":186,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":177,"canonicalId":178,"canonicalUrl":179,"publisher":180,"sourceType":181,"publicationDate":182,"lastChecked":22},{"title":189,"canonicalId":190,"canonicalUrl":191,"publisher":192,"sourceType":193,"publicationDate":194,"lastChecked":22},[291,313,330],{"safetyId":292,"observableTrigger":293,"careTier":294,"action":295,"applicablePopulations":296,"excludedPopulations":298,"locale":6,"checkedAt":22,"expiresAt":301,"sources":302},"us-candida-supplement-review-routine","Before starting a dietary supplement marketed for Candida, biofilms, die-off, gut health, or probiotic effects, the person takes a prescription or over-the-counter medicine, uses another supplement, is pregnant or breastfeeding, is a child, or has planned surgery or a recent change in health.","routine","Ask a physician, pharmacist, registered dietitian, or other qualified health professional to review the exact product label, full medicine and supplement list, health conditions, and planned surgery before use.",[297],"people in the United States considering an ingestible dietary supplement marketed for a Candida-related purpose who meet at least one listed trigger",[299,300],"people considering a conventional food rather than a dietary supplement","users with a serious reaction or acute crisis, who need the applicable faster route","2027-01-15",[303,309],{"title":304,"canonicalId":305,"canonicalUrl":306,"publisher":307,"sourceType":181,"publicationDate":308,"lastChecked":22},"FDA 101: Dietary Supplements","FDA consumer update: FDA 101 Dietary Supplements","https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements","U.S. Food and Drug Administration","2022-06-02",{"title":310,"canonicalId":311,"canonicalUrl":312,"publisher":307,"sourceType":181,"publicationDate":308,"lastChecked":22},"Mixing Medications and Dietary Supplements Can Endanger Your Health","FDA consumer update: mixing medications and dietary supplements","https://www.fda.gov/consumers/consumer-updates/mixing-medications-and-dietary-supplements-can-endanger-your-health",{"safetyId":314,"observableTrigger":315,"careTier":316,"action":317,"applicablePopulations":318,"excludedPopulations":320,"locale":6,"checkedAt":22,"expiresAt":301,"sources":323},"us-candida-supplement-serious-reaction-prompt","While using a dietary supplement marketed for a Candida-related purpose, the person develops throat, lip, or tongue swelling; wheezing; fainting; chest pain; shortness of breath; severe persistent vomiting, diarrhea, or abdominal pain; blood in urine, stool, vomit, or sputum; yellow skin or eyes; or slurred speech, one-sided weakness, or sudden vision loss.","prompt","Stop using the supplement and seek immediate medical care; after immediate care is addressed, report the suspected reaction through the FDA Safety Reporting Portal.",[319],"people in the United States using an ingestible dietary supplement marketed for a Candida, biofilm, die-off, gut-health, or probiotic purpose who develop a listed serious reaction",[321,322],"people with mild self-limited symptoms not included in the FDA serious-reaction list","people not using a dietary supplement",[324,325],{"title":304,"canonicalId":305,"canonicalUrl":306,"publisher":307,"sourceType":181,"publicationDate":308,"lastChecked":22},{"title":326,"canonicalId":327,"canonicalUrl":328,"publisher":307,"sourceType":181,"publicationDate":329,"lastChecked":22},"How to Report a Problem with Dietary Supplements","FDA dietary-supplement adverse-event reporting page","https://www.fda.gov/food/dietary-supplements/how-report-problem-dietary-supplements","2025-03-13",{"safetyId":331,"observableTrigger":332,"careTier":333,"action":334,"applicablePopulations":335,"excludedPopulations":337,"locale":6,"checkedAt":22,"expiresAt":339,"sources":340},"us-broad-candida-acute-crisis-emergency","A person describing Candida die-off or worsening during a Candida-labelled diet, supplement, probiotic, or antifungal says they are thinking about suicide, cannot stay safe, or are in acute emotional crisis.","emergency","Call or text 988, or use 988 Lifeline chat, now for free, confidential crisis support available 24 hours a day.",[336],"people in the United States who disclose the observable crisis trigger while discussing self-labelled Candida die-off or treatment-related worsening",[338],"people who use a die-off label or report worsening but do not disclose suicidal thoughts, inability to stay safe, or acute emotional crisis","2026-10-15",[341],{"title":342,"canonicalId":343,"canonicalUrl":344,"publisher":342,"sourceType":345,"publicationDate":346,"lastChecked":22},"988 Suicide & Crisis Lifeline","US three-digit crisis service 988","https://988lifeline.org/","official-care-service","2022-07-16",[348,351,354],{"rel":349,"hreflang":6,"href":350},"alternate","https://candipedia.org/en/symptoms-conditions/sifo/",{"rel":349,"hreflang":352,"href":353},"pl-PL","https://candipedia.org/pl/objawy-i-problemy/sifo/",{"rel":349,"hreflang":355,"href":350},"x-default",1784685064867]